SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT03029858

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Programmed Death-ligand 1(PD-L1) and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced Non-small Cell Lung Cancer (NSCLC) Patients

The study will investigate whether PD-L1 and other immuno-markers will be influenced by osimertinib treatment in advanced epidermal growth factor receptor (EGFR)T790M positive advanced NSCLC patients. In addition, we will explore whether PD-L1 and other immuno-markers can predict the safety and efficacy of subsequent use of immune checkpoint inhibitors at the time of PD due to osimertinib resistance.

NCT03029858 Small Cell Lung Cancer, Polygonal Type
MeSH:Lung Neoplasms Small Cell Lung Carcinoma
HPO:Neoplasm of the lung Small cell lung carcinoma

1 Interventions

Name: No interventions will be taken in this Observational study

Description: TAGRISSO(osimertinib/AZD9291)
Type: Other


Primary Outcomes

Description: Measure PD-L1 value Change by tumor cells(TC)/immune cells(IC) staining from the baseline to progressive disease(PD)

Measure: Measure PD-L1 value

Time: baseline and PD,up to 24 months

Description: Measure PD-L1 expression positive rate (%) change from the baseline to progressive disease(PD)

Measure: Measure PD-L1 expression positive rate (%)

Time: baseline and PD,up to 24 months

Time Perspective: Other

Case-Only


There is one SNP

SNPs


1 T790M

Small Cell Lung Cancer, Polygonal Type Lung Neoplasms Small Cell Lung Carcinoma Investigate whether PD-L1 and other immuno-markers will be influenced by osimertinib treatment in advanced EGFR T790M positive advanced NSCLC patients. --- T790M ---



HPO Nodes


HPO: